Overview / Abstract: |
Treatment selection is largely dependent on the goals of therapy; however, sequencing of standard therapies with newly approved therapies as patients’ progress is a key factor in improving quality of care. The recent approval of new agents and advances in biomarker detection have supported the individualization of treatment and subsequent improvements in survival for patients with gastrointestinal cancers. |
Expiration |
Feb 28, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
AACME - 1.25 AMA PRA Category 1 Credit(s) TM, ACPE - 1.25 hours (0.125 CEUs), ANCC - 1.2 contact hours. Designated for 0.9 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. |
Accreditation |
ACCME, ANCC, ACPE |
Presenters / Authors / Faculty |
Al B. Benson III, MD, FACP, FASCO |
Activity Specialities / Related Topics |
Gastroenterology / GI, Oncology / Cancer / Radiation Therapy, Pharmacology |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. |
Keywords / Search Terms |
Rockpointe Free CME, CME, Gastrointestinal Cancer, Nursing, Nurse Practitioner, Pharmacist, Pharmacology, Oncology, Free CE CME |